Antibody-based targeted therapy for gastric cancer

Lordick, Florian; Peschel, Christian; Siewert, J. R.

doi:10.1007/s10120-005-0345-4

Cited by 9 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ob mit neuen biologisch zielgerichteten Therapien ein weiterer Zugewinn zu erwarten ist, ist noch nicht ausreichend evaluiert [28]. Histopathologisch verifizierbares Ansprechen auf eine neoadjuvante Bestrahlung ist ausschließlich beim Konzept der konventionell fraktionierten Radiochemotherapie zu erwarten.…”

Section: Magenkarzinomunclassified

Response-Vorhersage – frühe Response-Evaluation

Siewert

Lordick

2006

Chirurg

View full text Add to dashboard Cite

Response to perioperative chemotherapy or chemoradiation can hardly be predicted on the basis of molecular marker analyses. In contrast, by means of metabolic and molecular imaging using positron emission tomography, response can be assessed as early as 14 days after the start chemotherapy for many tumors. There is no doubt that the prognosis of patients with surgically resected tumors is much better in the case of a response to chemotherapy or chemoradiation. Important consequences can be deduced from this regarding the indications for perioperative therapies, the radicality of surgery or the surgical indications per se. In the following, we delineate the current knowledge on response prediction and early response evaluation in selected tumor entities and draw possible conclusions for clinical practice and future clinical studies.

show abstract

Section: Magenkarzinomunclassified

Response-Vorhersage – frühe Response-Evaluation

Siewert

Lordick

2006

Chirurg

View full text Add to dashboard Cite

show abstract

“…Bevacizumab (anti-VEGF mAb) has been successfully approved for clinically treating many malignant tumors [13,14]. Monoclonal antibodies are currently the fastest expanding class of biopharmaceuticals [15] and regarded as the most commonly used and versatile targeted therapies in the treatment of tumors [16]. Nonetheless, they have some drawbacks such as high cost of production, immunogenecity and large size, as the latter disturb efficient tissue penetration [17,18].…”

Section: Introductionmentioning

confidence: 99%

A conformation-based phage-display panning to screen neutralizing anti-VEGF VHHs with VEGFR2 mimicry behavior

Shahangian

Sajedi

Hasannia

et al. 2015

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…[9] Overexpression of human epidermal growth factor receptor 2 (HER2) as a result of amplification of the HER2 gene (ERBB2; also known as HER2 neu) appears to mediate the initiation, progression, and metastasis of many types of cancer. [9][10][11][12] Approximately 20-30% of primary breast cancers are HER2-positive and this is associated with a more aggressive form of the disease and a poorer prognosis for the patient. [10,13] A wider variation in the overexpression of HER2 has been reported in gastric cancer (9-38%), possibly as result of smaller sample sizes, greater histologic variation of gastric tissue and differences in immunohistochemistry (IHC) scoring technique.…”

mentioning

confidence: 99%